Barlet 1990.

Methods	Multicentre study. Double blinded: yes.
Participants	N=263 European men with symptomatic BPH, age > 50. Age range 50‐85, mean 67. Lost to follow‐up: 8 (3%).
Interventions	Control: placebo (n=132). Treatment: P. africanum extract (Tadenan) 100 mg twice daily (n=131). Treatment duration: 60 days.
Outcomes	Overall improvement in symptoms (MD/subject ‐ rating); Nocturia; peak urine flow; residual volume. Adverse events.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear